RHO CAPITAL PARTNERS INC recently filed their 13F report for the third quarter of 2022, which ended on 2022-09-30.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
152 WEST 57TH STREET NEW YORK, NY 10019
As of the latest 13F report, the guru’s equity portfolio contained 4 stocks valued at a total of $63.00Mil. The top holdings were CHPT(95.45%), LVO(4.22%), and SENS(0.34%).
According to GuruFocus data, these were RHO CAPITAL PARTNERS INC’s top five trades of the quarter.
NGM Biopharmaceuticals Inc
The guru sold out of their 3,766,666-share investment in NAS:NGM. Previously, the stock had a 39.74% weight in the equity portfolio. Shares traded for an average price of $13.86 during the quarter.
On 11/04/2022, NGM Biopharmaceuticals Inc traded for a price of $5.275 per share and a market cap of $427.95Mil. The stock has returned -73.52% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, NGM Biopharmaceuticals Inc has a price-book ratio of 1.45, a EV-to-Ebitda ratio of -0.90 and a price-sales ratio of 6.12.
The price-to-GF Value ratio is 0.44, earning the stock a GF Value rank of 4.
Mersana Therapeutics Inc
The guru sold out of their 796,458-share investment in NAS:MRSN. Previously, the stock had a 2.2% weight in the equity portfolio. Shares traded for an average price of $3.77 during the quarter.
On 11/04/2022, Mersana Therapeutics Inc traded for a price of $7.42 per share and a market cap of $728.77Mil. The stock has returned -22.76% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Mersana Therapeutics Inc has a price-book ratio of 5.43, a EV-to-Ebitda ratio of -2.83 and a price-sales ratio of 105.69.
ChargePoint Holdings Inc
RHO CAPITAL PARTNERS INC reduced their investment in NYSE:CHPT by 20,089,084 shares. The trade had a 63.88% impact on the equity portfolio. During the quarter, the stock traded for an average price of $23.39.
On 11/04/2022, ChargePoint Holdings Inc traded for a price of $12.34 per share and a market cap of $4.19Bil. The stock has returned -49.86% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, ChargePoint Holdings Inc has a price-book ratio of 10.63, a EV-to-Ebitda ratio of -14.38 and a price-sales ratio of 12.30.
ON24 Inc
The guru sold out of their 3,637,894-share investment in NYSE:ONTF. Previously, the stock had a 11.81% weight in the equity portfolio. Shares traded for an average price of $27.86 during the quarter.
On 11/04/2022, ON24 Inc traded for a price of $7.12 per share and a market cap of $338.08Mil. The stock has returned -61.49% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, ON24 Inc has a price-book ratio of 1.06, a EV-to-Ebitda ratio of -0.31 and a price-sales ratio of 1.66.
Cara Therapeutics Inc
The guru sold out of their 1,499,058-share investment in NAS:CARA. Previously, the stock had a 1.96% weight in the equity portfolio. Shares traded for an average price of $13.96 during the quarter.
On 11/04/2022, Cara Therapeutics Inc traded for a price of $9.14 per share and a market cap of $489.98Mil. The stock has returned -48.33% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Cara Therapeutics Inc has a price-book ratio of 2.39, a EV-to-Ebitda ratio of -5.15 and a price-sales ratio of 9.91.
The price-to-GF Value ratio is 0.38, earning the stock a GF Value rank of 4.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
